Erratum: TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis (Theranostics (2019) 9:22 (6676-6689) DOI: 10.7150/thno.34020)

研究成果: 雜誌貢獻評論/辯論同行評審

摘要

The authors wish to inform readers of a correction to the study. The informed consent and the IRB approval number in the Materials and methods section, should be revised as follows: The human tissue biopsy samples used in this study were collected as part of a study approved by the human ethics committee of Taipei Medical University Joint Institutional Review Board (TMU-JIRB No. N201701061). The waiver of informed consent for the study was monitored by TMU-JIRB. The authors regret the inconsistency and apologize for not identifying the issue earlier in the publication process.

原文英語
頁(從 - 到)2079
頁數1
期刊Theranostics
11
發行號5
DOIs
出版狀態已發佈 - 一月 1 2021

ASJC Scopus subject areas

  • 醫藥(雜項)
  • 藥理學、毒理學和藥劑學(雜項)

指紋

深入研究「Erratum: TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis (Theranostics (2019) 9:22 (6676-6689) DOI: 10.7150/thno.34020)」主題。共同形成了獨特的指紋。

引用此